CEO Urges $31 Million Investment In Malaysia Biotech Sector
This article was originally published in PharmAsia News
A biotech CEO says Malaysia needs as much as $31 million in public-sector investment within the next three years if the industry is to reach a commercialization level. Datuk Iskandar Mizal Mahmood, CEO of Malaysian Biotech, spoke of a need of $25 million to $31 million to build an infrastructure and collaborate with foreign entities to leverage the nation's tissue-banking sector. He said Malaysia needs to make a strong effort to complement the efforts of the National Tissue Bank and Nuklear Malaysia to commercialize tissue banking as part of a huge global market for tissue-engineered products. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.